Damora Therapeutics CEO buys 12,500 shares

Individual purchase prices ranged from $20.10 to $20.40, and the reported post-transaction amount includes 500,000 RSUs.

Rhea-AI Filing Summary

Damora Therapeutics, Inc.'s Director, President and CEO Jennifer Jarrett purchased 12,500 ordinary shares on the open market on September 25, 2026, using personal funds, at a weighted average price of $20.23 per share. Her reported post-transaction total was 512,500, including 500,000 restricted stock units; each RSU represents the right to receive one ordinary share at settlement. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 12,500 shares

Net Buy 1 txn

Insider Jarrett Jennifer

Role Director, President and CEO

Bought 12,500 shs ($253K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares F1, F2, F3	12,500	$20.23	$253K

Holdings After Transaction: Ordinary Shares — 512,500 shares (Direct)

Footnotes (3)

1. F1. Represents shares purchased on the open market at prevailing market prices using personal funds.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.10 to $20.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
3. F3. Includes 500,000 restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one ordinary share of the Issuer.

Key Figures

Ordinary shares purchased: 12,500 shares Weighted average purchase price: $20.23 per share Purchase price range: $20.10 to $20.40 per share +2 more

5 metrics

Ordinary shares purchased 12,500 shares September 25, 2026

Weighted average purchase price $20.23 per share September 25, 2026

Purchase price range $20.10 to $20.40 per share Multiple transactions on September 25, 2026

Reported post-transaction total 512,500 shares, including 500,000 restricted stock units Following the September 25, 2026 purchase

Restricted stock units 500,000 units Included in the reported post-transaction total

Key Terms

weighted average price, restricted stock units, prevailing market prices, settlement

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

restricted stock units financial

"Includes 500,000 restricted stock units ("RSUs") previously granted to the Reporting Person."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

prevailing market prices financial

"at prevailing market prices using personal funds."

The current prices at which a security or asset is being actively bought and sold in the open market, reflecting real‑time supply and demand—like the price you’d pay for an item in a busy marketplace. Investors care because these prices determine what they can actually sell or buy, set the value of holdings for accounting and lending, and influence decisions about timing trades and measuring gains or losses.

settlement financial

"Each RSU represents the right to receive, at settlement, one ordinary share of the Issuer."

Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DMRA shares did Jennifer Jarrett buy, and at what price?

Jennifer Jarrett purchased 12,500 ordinary shares on September 25, 2026, at a weighted average price of $20.23 per share. The shares were bought in multiple open-market transactions at prices ranging from $20.10 to $20.40, inclusive, using personal funds.

What did Jennifer Jarrett's 500,000 DMRA restricted stock units represent?

Each of the 500,000 restricted stock units included in her reported post-transaction total represents the right to receive one ordinary share at settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 07:00 AM Accepted by SEC EDGAR 09/28/2026 - 07:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarrett Jennifer

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.

100 FIFTH AVENUE, SUITE 700

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Director, President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/25/2026		P(1)		12,500	A	$20.23(2)	512,500(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares purchased on the open market at prevailing market prices using personal funds.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.10 to $20.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. Includes 500,000 restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one ordinary share of the Issuer.

	/s/ Garrett Winslow, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)